JP4971542B2 - ニコチン中毒の治療及び予防のためのハプテン−キャリア複合体 - Google Patents

ニコチン中毒の治療及び予防のためのハプテン−キャリア複合体 Download PDF

Info

Publication number
JP4971542B2
JP4971542B2 JP2000584928A JP2000584928A JP4971542B2 JP 4971542 B2 JP4971542 B2 JP 4971542B2 JP 2000584928 A JP2000584928 A JP 2000584928A JP 2000584928 A JP2000584928 A JP 2000584928A JP 4971542 B2 JP4971542 B2 JP 4971542B2
Authority
JP
Japan
Prior art keywords
nicotine
hapten
antibody
carrier
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000584928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002531421A (ja
JP2002531421A5 (enExample
Inventor
ソフィアーヌ エニファー
アリ イブラヒム ファットム
ロバート ビー． ナソ
Original Assignee
ナビ バイオファーマシューティカルズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22747358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4971542(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ナビ バイオファーマシューティカルズ filed Critical ナビ バイオファーマシューティカルズ
Publication of JP2002531421A publication Critical patent/JP2002531421A/ja
Publication of JP2002531421A5 publication Critical patent/JP2002531421A5/ja
Application granted granted Critical
Publication of JP4971542B2 publication Critical patent/JP4971542B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/816—Alkaloids, amphetamines, and barbiturates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000584928A 1998-12-01 1999-12-01 ニコチン中毒の治療及び予防のためのハプテン−キャリア複合体 Expired - Fee Related JP4971542B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/201,800 1998-12-01
US09/201,800 US6232082B1 (en) 1998-12-01 1998-12-01 Hapten-carrier conjugates for treating and preventing nicotine addiction
PCT/US1999/028272 WO2000032239A1 (en) 1998-12-01 1999-12-01 Hapten-carrier conjugates for treating and preventing nicotine addiction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010264835A Division JP2011079849A (ja) 1998-12-01 2010-11-29 ニコチン中毒の治療及び予防のためのハプテン−キャリア複合体

Publications (3)

Publication Number Publication Date
JP2002531421A JP2002531421A (ja) 2002-09-24
JP2002531421A5 JP2002531421A5 (enExample) 2007-01-18
JP4971542B2 true JP4971542B2 (ja) 2012-07-11

Family

ID=22747358

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000584928A Expired - Fee Related JP4971542B2 (ja) 1998-12-01 1999-12-01 ニコチン中毒の治療及び予防のためのハプテン−キャリア複合体
JP2010264835A Pending JP2011079849A (ja) 1998-12-01 2010-11-29 ニコチン中毒の治療及び予防のためのハプテン−キャリア複合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010264835A Pending JP2011079849A (ja) 1998-12-01 2010-11-29 ニコチン中毒の治療及び予防のためのハプテン−キャリア複合体

Country Status (26)

Country Link
US (7) US6232082B1 (enExample)
EP (3) EP1512414A1 (enExample)
JP (2) JP4971542B2 (enExample)
KR (1) KR100656836B1 (enExample)
CN (2) CN1220521C (enExample)
AT (1) ATE279211T1 (enExample)
AU (1) AU763001B2 (enExample)
BR (1) BR9915852A (enExample)
CA (1) CA2352765C (enExample)
DE (1) DE69921178T2 (enExample)
DK (1) DK1135166T3 (enExample)
EA (1) EA004956B1 (enExample)
ES (1) ES2229800T3 (enExample)
HK (2) HK1043061B (enExample)
HU (1) HUP0104365A3 (enExample)
IL (2) IL143474A0 (enExample)
ME (1) MEP34208A (enExample)
MX (1) MXPA01005511A (enExample)
NO (1) NO331998B1 (enExample)
NZ (1) NZ512103A (enExample)
PL (1) PL199253B1 (enExample)
PT (1) PT1135166E (enExample)
RS (1) RS51273B (enExample)
TR (1) TR200102411T2 (enExample)
WO (1) WO2000032239A1 (enExample)
ZA (1) ZA200104477B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011079849A (ja) * 1998-12-01 2011-04-21 Nabi Biopharmaceuticals ニコチン中毒の治療及び予防のためのハプテン−キャリア複合体

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
AU2002251821A1 (en) * 2001-01-26 2002-08-06 The Scripps Research Institute Nicotine immunogens and antibodies and uses thereof
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US20030148260A1 (en) * 2001-08-07 2003-08-07 Bernard Levin Method of diagnosing colorectal adenomas and cancer using proton maggnetic resonance spectroscopy
CA2477268A1 (en) * 2002-03-01 2003-10-09 The Board Of Regents Of The University Of Nebraska Compositions and compounds for use as molecular adjuvant for a nicotine vaccine
IN2008CN05409A (enExample) * 2002-07-18 2015-10-02 Cytos Biotechnology Ag
US20040115244A1 (en) * 2002-12-17 2004-06-17 Holgate Eric Jamison Methods and compositions for nicotine replacement therapy
ATE359075T1 (de) * 2002-12-20 2007-05-15 Niconovum Ab Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
WO2005040338A2 (en) * 2003-05-21 2005-05-06 The Scripps Research Institute Constrained alkaloid immunogens and antibodies and uses thereof
GB0313916D0 (en) * 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
US7220842B2 (en) * 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine
US7678551B2 (en) * 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
WO2006091796A2 (en) * 2005-02-22 2006-08-31 Acucela, Inc. Compositions and methods for diagnosing and treating retinal diseases
EP1963308A4 (en) * 2005-11-28 2010-12-15 Nabi Biopharmaceuticals METHOD FOR PRODUCING A NICOTINE HAPTEN
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
WO2007100755A1 (en) * 2006-02-27 2007-09-07 Nabi Biopharmaceuticals Method for decreasing the toxic effects of nicotine on fetuses in pregnant women
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
JP2009534309A (ja) * 2006-03-31 2009-09-24 マサチューセッツ インスティテュート オブ テクノロジー 治療剤の標的化送達のためのシステム
EP1849780A1 (en) 2006-04-21 2007-10-31 De Staat der Nederlanden, vert. door de minister van VWS Vaccine against nicotine addiction
EP1854478A1 (en) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
EP2019691B1 (en) 2006-05-15 2020-08-12 Massachusetts Institute of Technology Polymers for functional particles
US20110052697A1 (en) * 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
US9381477B2 (en) * 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
WO2008019142A2 (en) * 2006-08-04 2008-02-14 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
EP2134830A2 (en) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oscillating cell culture bioreactor
EP2144600A4 (en) * 2007-04-04 2011-03-16 Massachusetts Inst Technology POLY (AMINIC ACID) TARGET MOLECULES
WO2008124634A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
EP2620157A3 (en) 2007-10-12 2013-10-16 Massachusetts Institute of Technology Vaccine nanotechnology
EP2319867A1 (en) * 2007-11-29 2011-05-11 Cytos Biotechnology AG Human monoclonal nicotine specific antibodies
EP2065398A1 (en) * 2007-11-29 2009-06-03 Cytos Biotechnology AG Human monoclonal nicotine specific antibodies
US20110086063A1 (en) * 2008-06-04 2011-04-14 Cornell University Vaccines for prevention and treatment of addiction
US20110182918A1 (en) 2008-06-13 2011-07-28 Nabi Biopharmaceuticals Personalized drug treatment and smoking cessation kit and method
JP2011524521A (ja) * 2008-06-13 2011-09-01 ナビ バイオファーマシューティカルズ 喫煙停止キットおよび方法
PL2313390T3 (pl) * 2008-08-08 2013-03-29 Novartis Ag Proces otrzymywania haptenów na bazie nikotyny
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) * 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
CA2745096C (en) 2008-12-09 2013-11-05 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
WO2011014679A1 (en) 2009-07-31 2011-02-03 Nabi Biopharmaceuticals Method and kit for treating nicotine addiction
MX343908B (es) * 2009-08-26 2016-11-28 Selecta Biosciences Inc * Composiciones que inducen la ayuda de las células t.
US20120225087A1 (en) * 2009-09-14 2012-09-06 The Scripps Research Institute Nicotine haptens, immunoconjugates and their uses
US20110182831A1 (en) * 2010-01-25 2011-07-28 Aradigm Corporation Systems and methods used in conjunction with nicotine vaccines for effecting cessation of tobacco use
WO2011116189A1 (en) 2010-03-17 2011-09-22 Cornell University Disrupted adenovirus-based vaccine against drugs of abuse
WO2011123042A1 (en) * 2010-04-01 2011-10-06 Independent Pharmaceutica Ab Vaccination procedure and products for use therein
GB201006324D0 (en) 2010-04-15 2010-06-02 Glaxosmithkline Biolog Sa Vaccine
NO2575876T3 (enExample) 2010-05-26 2018-05-05
TWI578997B (zh) * 2010-06-04 2017-04-21 輝瑞疫苗有限責任公司 用於預防或治療菸鹼成癮之共軛體
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
US20140039063A1 (en) * 2011-01-04 2014-02-06 National Jewish Health Leukotrienes and asthma exacerbation risk
KR20140027211A (ko) 2011-04-04 2014-03-06 유니버시티 오브 아이오와 리써치 파운데이션 백신 면역원성의 개선 방법
US20130039954A1 (en) 2011-07-29 2013-02-14 Selecta Biosciences, Inc. Control of antibody responses to synthetic nanocarriers
WO2013130393A1 (en) 2012-02-28 2013-09-06 Cornell University Aav-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
WO2013154744A1 (en) * 2012-04-13 2013-10-17 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
TWI600905B (zh) * 2012-09-21 2017-10-01 國立臺灣師範大學 聚合半抗原成為免疫原的技術方法
US9303013B2 (en) * 2014-05-16 2016-04-05 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
WO2015179403A1 (en) * 2014-05-19 2015-11-26 The Scripps Research Institute Enantiopure haptens for nicotine vaccine development
CN104402992B (zh) * 2014-11-28 2018-09-18 杭州安旭科技有限公司 一种合成大麻抗原的合成方法及合成大麻抗原的应用
EP3247380A1 (en) * 2015-01-20 2017-11-29 Universiteit Antwerpen Neuregulin in the treatment of fibrotic disorders
CN106496309A (zh) * 2016-11-24 2017-03-15 北京开景基因技术有限公司 微球抗原及其制备方法以及抗可替宁抗体的制备方法
CA3066915A1 (en) 2017-06-11 2018-12-20 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
WO2019036419A1 (en) 2017-08-15 2019-02-21 Kalnik Matthew W NEW NICOTINE BINDING ANTIBODIES
CN108362891B (zh) * 2017-12-27 2020-09-25 北京勤邦生物技术有限公司 一种泼尼松的磁免疫化学发光检测试剂盒及其应用
US11333372B2 (en) 2018-03-09 2022-05-17 Scot Matthew Duncan Energy recovery high efficiency dehumidification system
US20220267474A1 (en) * 2018-06-06 2022-08-25 Antidote Therapeutics, Inc. Methods for improving circulation and treating cardiovascular disease
KR102237349B1 (ko) 2019-10-23 2021-04-07 한국과학기술연구원 니코틴 중독 또는 금단 증상 예방 또는 치료용 약학 조성물
US20220265601A1 (en) * 2021-02-10 2022-08-25 David Alan Heldreth, JR. Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.
CN115583992A (zh) * 2022-11-02 2023-01-10 江南大学 一种氧化还原响应的载体蛋白及其在制备疫苗中的应用
CN116747315A (zh) * 2023-06-20 2023-09-15 中国科学院长春应用化学研究所 高dar值的抗体-免疫调节药物偶联物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014216A2 (en) * 1996-09-30 1998-04-09 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4375414A (en) 1971-05-20 1983-03-01 Meir Strahilevitz Immunological methods for removing species from the blood circulatory system and devices therefor
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US3888886A (en) 1972-06-08 1975-06-10 Mobil Oil Corp Oxidation of alkanes to maleic anhydride using promoted vanadium-phosphorus catalyst
US4045420A (en) 1973-05-29 1977-08-30 Syva Company Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds polypeptide and derivatives thereof
US3888866A (en) 1973-06-01 1975-06-10 Syva Co Nitrogen derivatives of benzoyl ecgonine
US4053459A (en) 1975-09-24 1977-10-11 Hoffmann-La Roche Inc. Antibody specific to methaqualone and its metabolites
US4235864A (en) 1978-04-10 1980-11-25 Research Corporation Simultaneous radio immunoassay of multiple antigens and _assay for cocaine metabolites
US4376825A (en) 1979-05-07 1983-03-15 Syva Company Enzyme amplification compounds for assays for androgens
US4666837A (en) 1982-05-24 1987-05-19 Smithkline-Rit DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits
SU1123704A1 (ru) 1983-04-08 1984-11-15 Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений Способ получени конъюгированных антигенов
EP0194158A3 (en) 1985-03-08 1988-02-24 Baylor College of Medicine Anti-nicotine and anti-cotinine antibodies (monoclonal and other), and their uses in nicotine and cotinine assays
US5019384A (en) 1986-06-30 1991-05-28 Massachusetts Institute Of Technology Immunonodulating compositions and their use
US4791067A (en) 1987-06-25 1988-12-13 Fisher Scientific Co. Agglutination immunoassay for hapten involving monoclonal antibody of IgA class reagent
EP0311383B1 (en) 1987-10-09 1993-10-06 Ube Industries, Ltd. Monoclonal antibody to methamphetamine, preparation of the same, assay method and assay kit of methamphetamine
US5268276A (en) 1988-09-16 1993-12-07 Jan Holmgren Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
EP0363041A1 (en) 1988-09-21 1990-04-11 Ube Industries, Ltd. Monoclonal antibody to morphine, preparation of monoclonal antibody, assaying kit and assaying method of morphine
GB9001694D0 (en) 1990-01-25 1990-03-28 Therapeutic Antibodies Inc Immunogenic compositions
CH678394A5 (enExample) 1990-08-22 1991-09-13 Cerny Erich H
US5674978A (en) 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US5290784A (en) * 1991-07-18 1994-03-01 Yueqian Qu Aconitane derivatives used as a medication to treat addiction
US5233042A (en) 1991-12-16 1993-08-03 Biosite Diagnostics, Inc. Cocaine derivatives
US5283066A (en) 1992-02-19 1994-02-01 Development Center For Biotechnology Method of stimulating an immune response by using a hapten
DE4216133A1 (de) 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen
WO1993023076A1 (en) 1992-05-20 1993-11-25 The Johns-Hopkins University Alternative receptor therapy
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
EP0613899B1 (en) 1993-03-04 2003-01-15 Matsushita Electric Industrial Co., Ltd. Cocaine derivative, protein conjugate thereof, monoclonal antibody producing hybridoma cell line, method for preparing the hybridoma cell line and monoclonal antibody
US5375414A (en) 1993-10-04 1994-12-27 Ford Motor Company Automotive engine exhaust aftertreatment system including hydrocarbon adsorber with internal engine purge flow control
EP0756629A1 (en) 1994-04-08 1997-02-05 Immunologic Pharmaceutical Corporation Pharmaceutical formulations for treating japanese cedar pollen allergy
US5510102A (en) 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
US5773003A (en) 1995-03-31 1998-06-30 Immulogic, Inc. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
DK1329226T3 (da) 1995-03-31 2007-09-24 Xenova Res Ltd Haptenbærerkonjugater til anvendelse i behandling af stofmisbrug
EP1015028A2 (en) * 1997-09-19 2000-07-05 Serex, Inc. Methods to improve immunogenicity of antigens and specificity of antibodies
US6232082B1 (en) * 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014216A2 (en) * 1996-09-30 1998-04-09 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011079849A (ja) * 1998-12-01 2011-04-21 Nabi Biopharmaceuticals ニコチン中毒の治療及び予防のためのハプテン−キャリア複合体

Also Published As

Publication number Publication date
CN1768861A (zh) 2006-05-10
DE69921178D1 (de) 2004-11-18
MEP34208A (en) 2011-02-10
HUP0104365A2 (hu) 2002-04-29
BR9915852A (pt) 2004-06-29
US7247502B2 (en) 2007-07-24
WO2000032239A9 (en) 2002-08-22
ATE279211T1 (de) 2004-10-15
EA004956B1 (ru) 2004-10-28
DK1135166T3 (da) 2005-02-14
HK1043061A1 (en) 2002-09-06
YU39601A (sh) 2003-10-31
US20030165950A1 (en) 2003-09-04
JP2002531421A (ja) 2002-09-24
ES2229800T3 (es) 2005-04-16
HK1042428A1 (en) 2002-08-16
IL143474A0 (en) 2002-04-21
EP1135166B9 (en) 2005-02-02
US8026109B2 (en) 2011-09-27
HK1091415A1 (zh) 2007-01-19
PT1135166E (pt) 2005-01-31
RS51273B (sr) 2010-12-31
PL349012A1 (en) 2002-06-17
HK1043061B (zh) 2006-07-07
EP1512414A1 (en) 2005-03-09
NO20012589D0 (no) 2001-05-25
EA200100610A1 (ru) 2002-04-25
HK1042428B (en) 2005-07-29
CA2352765C (en) 2011-02-15
EP1135166A1 (en) 2001-09-26
WO2000032239A1 (en) 2000-06-08
US6232082B1 (en) 2001-05-15
CA2352765A1 (en) 2000-06-08
US20020004208A1 (en) 2002-01-10
AU763001B2 (en) 2003-07-10
KR20010090854A (ko) 2001-10-19
EP2324855A1 (en) 2011-05-25
DE69921178T2 (de) 2005-11-17
NO20012589L (no) 2001-07-20
US20050136047A1 (en) 2005-06-23
US6773891B2 (en) 2004-08-10
ZA200104477B (en) 2002-01-16
PL199253B1 (pl) 2008-08-29
US7776620B2 (en) 2010-08-17
TR200102411T2 (tr) 2002-01-21
HUP0104365A3 (en) 2002-05-28
NO331998B1 (no) 2012-05-21
US20110217320A1 (en) 2011-09-08
CN1329508A (zh) 2002-01-02
JP2011079849A (ja) 2011-04-21
MXPA01005511A (es) 2004-08-19
CN1220521C (zh) 2005-09-28
KR100656836B1 (ko) 2006-12-12
AU2033500A (en) 2000-06-19
US20110002957A1 (en) 2011-01-06
CN100586481C (zh) 2010-02-03
NZ512103A (en) 2003-09-26
IL143474A (en) 2006-06-11
US6518031B2 (en) 2003-02-11
EP1135166B1 (en) 2004-10-13
US20080026000A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
JP4971542B2 (ja) ニコチン中毒の治療及び予防のためのハプテン−キャリア複合体
JP6564396B2 (ja) ニコチンワクチン開発のためのエナンチオピュアなハプテン
HK1075824A (en) Hapten-carrier conjugates for treating and preventing nicotine addiction
HK1091415B (en) Hapten-carrier conjugates for treating and preventing nicotine addiction

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20050510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100830

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100928

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101028

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110805

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120328

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120406

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150413

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees